Fibrosis: Oncodesign and TiumBio sign collaboration agreement for R&D of drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix® drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates. This initial phase of the collaboration will be funded by TiumBio.
Here is our September issue which echoes our #InvestorDay 2021. As usual, Philippe Genne has concocted an editorial entitled “Little GrassHopper”: a philosophical angle on the meaning of life and the importance of the individual in society.
Here is our April 2020 issue which details the new organization of the Group into 3 Business Units. Interviews and articles on the menu. Anatomy of the new face of Oncodesign: BU Service, BU Biotech & BU Artificial Intelligence. Without forgetting the editorial by Ph. Genne entitled “how much is…